Alvocidib - CAS 146426-40-6
Catalog number: B0084-059050
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Publictions citing BOC Sciences Products
  • >> More
Light yellow to yellow solid
Flavopiridol; HMR 1275.
For research used only
Current Developer:
Sanofi-Aventis Inc.
1. Flavonoids from Achyrocline satureioides: promising biomolecules for anticancer therapy
Juliana Poglia Carini*, F´ abio Klamt, Valquiria Linck Bassani. RSC Adv.,2014, 4,3131–3144
Flavopiridol is another semisynthetic avonoid with potential anticancer properties. The compound is a flavone derived from rohitukine, a natural anticancer agent isolated from an Indian tree. Due to its interesting biological properties both in vitro and in vivo, as cell cycle arrest in G1 and G2 phases, cytotoxicity against the majority of tumor cell lines in the nanomolar range, suppression of the tumor growth in animals and synergistic activity with most anticancer drugs and radiation, flavopiridol was the first cyclin-dependent kinase (CDK) inhibitor to be tested in human clinical trials. However, the molecule in Phase II clinical trials was ineffective against cancer and presented high toxicity to patients. Nevertheless, currently 60 anticancer clinical trials can be found with flavopiridol, alone or combined with other drugs, whereby 6 of them have shown to be active in the recruiting phase.
2. Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways
Wen Jiang, Ming Hua. RSC Adv., 2012, 2, 7948–7963
Early investigation showed that genistein inhibited the efflux of daunorubicin from small-cell lung cancer GL4/ADR cells, in which MRP was overexpressed, in a competitive manner. The same result of inhibition of daunorubicin by genistein competitively was also observed in plasma membrane vesicles from marine MRP-transfected NIH3T3 cells. Follow-up study confirmed that genistein but not genistin, together with kaempferol and flavopiridol (synthetic flavonoid derivative) could affect MRP-mediated transport of anticancer drugs by a direct interaction with MRP. Moreover, chrysin was reported to inhibit the accumulation of the MRP2 substrate CMFDA in Caco-2 cells in a dose-dependent manner. The maximal accumulation, which could also be achieved by specific MRP inhibitor-MK571, was observed in the presence of 250 mM chrysin. Interestingly, chrysin was also found to increase the expression of MRP2 5 fold in Caco-2 cells after long-term treatment. Over a time period of 48 h, the inhibition of transporter function overtook the enhanced expression of MRP2 by chrysin, resulting in an increased accumulation of topotecan. Therefore, chrysin seemed to play a dual role in regulating MRP2 in Caco-2 cells.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products

CAS 345627-80-7 SNS-032

(CAS: 345627-80-7)

SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. ...

CAS 1401033-86-0 AMG 925

AMG 925
(CAS: 1401033-86-0)

AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. AMG 925 inhibited AML xenograft tumor growth by 96...

CAS 496864-16-5 Aloisine A

Aloisine A
(CAS: 496864-16-5)

Aloisine a is a cell-permeable pyrrolo-pyrazine compound that acts as a potent, selective, reversible, and ATP-competitive inhibitor of cyclin dependent kinases...

CAS 802539-81-7 Milciclib

(CAS: 802539-81-7)

Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activi...


ICEC-0942 is a small-molecule cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. Pre-clinical study in Acute Myeloid Leukaemia (AML) model...

Senexin A
(CAS: 1366002-50-7)

Senexin A is a selective Cell division protein kinase 8 (CDK8) inhibitor with IC50 value of 280 nM. Senexin A can bind to cdk19 in an ATP-competitive manner and...

(CAS: 1229665-91-1)

CGP-79807 is a potent CDC2 protein kinase inhibitor that originated by Novartis. In Sep 2000, Preclinical development for Cancer in Switzerland was on-going, bu...

CAS 143621-35-6 Triapine

(CAS: 143621-35-6)

3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a ribonucleotide reductase inhibitor and iron chelator with anti-tumor activity.

CAS 1374639-75-4 LEE011 succinate

LEE011 succinate
(CAS: 1374639-75-4)

LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific in...

CAS 161058-83-9 NU2058

(CAS: 161058-83-9)

NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.

CAS 186692-46-6 Seliciclib

(CAS: 186692-46-6)

Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...

CAS 779353-01-4 Dinaciclib

(CAS: 779353-01-4)

Dinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases ...

CAS 1211443-80-9 LEE011 hydrochloride

LEE011 hydrochloride
(CAS: 1211443-80-9)

CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation preve...

CAS 602306-29-6 AZD5438

(CAS: 602306-29-6)

AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an eff...

CAS 1414943-88-6 BAY-1143572

(CAS: 1414943-88-6)

BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...

CAS 131740-09-5 Flavopiridol Hydrochloride

Flavopiridol Hydrochloride
(CAS: 131740-09-5)

Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/...

CAS 1431697-85-6 AT7519 trifluoroacetate

AT7519 trifluoroacetate
(CAS: 1431697-85-6)

AT7519 is an ATP competitive CDK inhibitor with a Ki value of 38 nM for CDK1. AT7519 is inactive against all non-CDK kinases with the exception of GSK3β (IC50 =...

CAS 1204918-72-8 SB1317

(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 1070790-89-4 CYC065

(CAS: 1070790-89-4)

CYC065 is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with potential antineoplastic and chemoprotective activities.

CAS 1604810-83-4 THZ1

(CAS: 1604810-83-4)

THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine ...

Chemical Structure

CAS 146426-40-6 Alvocidib

Quick Inquiry

Verification code

Featured Items